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ABSTRACT
Acute respiratory distress syndrome 
(ARDS) is a condition recognised for al-
most fifty years, and is related to high mor-
bidity and mortality in children. From its 
recognition, medical experts tried to make 
joint efforts to make recommendations 
and optimize treatment in children and 
adult population. The new definition of 
ARDS suggests treatment by introducing 
three levels of severity, according to PaO2/
FiO2 and positive end-expiratory pres-
sure. Lung-protective ventilation remains 
crucial in achieving better outcome in pae-
diatric acute respiratory distress syndrome 
(PARDS), but promising therapies based 
on paediatric studies include non-invasive 
ventilation, endotracheal surfactant, high-
frequency oscillatory ventilation (HFOV), 
and use of ECMO as „rescue“ therapy. 
Nevertheless, PARDS is a real challenge for 
the paediatric critical care provider, and 
even if current state-of-the-art treatment 
methods are delivered, this disease often 
leads to fatal outcome. 
We report the case of an 11-month-old 
female infant who developed ARDS, was 
treated by current up-to-date treatment 
methods, including ECMO, and despite 
this, succumbed to her illness. With this 
case report we would like once more to 
bring to consideration the current knowl-
edge on etiology, epidemiology, diagnosis 
and treatment of ARDS in children, and 
emphasize the high morbidity and mortal-
ity related to this syndrome.
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INTRODUCTION
Acute respiratory distress syndrome 
(ARDS) is a permeability pulmonary oede-
ma, characterized by increased permeabil-
ity of pulmonary capillary endothelial cells 
and
alveolar epithelial cells, leading to hypox-
emia that is refractory to usual oxygen 
therapy. (1)
The incidence of ARDS in the overall pae-
diatric population is relatively low, with 
estimates ranging between 2.9 and 9.5 
cases/100 000 children per year. (2) The 
new Berlin definition of ARDS has been 
published recently. This definition has sug-
gested severity-oriented respiratory treat-
ment by introducing three levels of sever-
ity (mild, moderate, and severe) according 
to PaO2/FiO2. A positive end-expiratory 
pressure (PEEP) with a minimum of 5 cm 
H2O is also required. By using the Berlin 
Definition instead of the American-Eu-
ropean Consensus Conference (AECC), 
stages of mild, moderate, and severe ARDS 
were associated with increased mortal-
ity (27%; 32%; and 45% respectively) and 
increased median duration of mechanical 
ventilation in survivors (5 days; 7 days; 
and 9 days respectively). (3) In treatment 
strategies, lung-protective ventilation is 
still crucial in achieving better outcome 
in ARDS. Open-lung ventilation strategy, 
characterized by sufficient positive end-
expiratory pressure to avoid atelectasis, a 
tidal volume that is limited to less than 5-7 
ml/kg per breath and a plateau pressure of 
30 cm of water or less, provides the greatest 
likelihood of survival and minimizes lung 
injury. (2) Regarding pulmonary-specific 
ancillary and non-pulmonary treatment, 
there are a few suggested options proposed 
by The Paediatric Acute Lung Injury Con-
sensus Conference Group (PALICC): 1) 
inhaled nitric oxide (iNO) for patients with 
documented pulmonary hypertension or 
severe right ventricular dysfunction; 2) 
maintaining a clear airway with cautions 
suctioning, 3) prone positioning for se-
lected patients in cases of severe paediatric 
acute respiratory syndrome (PARDS), 4) 
effective targeted sedation and neuromus-
cular blockade (in selected cases), 5) enter-
al nutrition when tolerated, 6) goal-direct-
ed fluid management-fluid balance titrated 
to maintain adequate intravascular volume 
while aiming to prevent positive fluid bal-
ance, and 7) blood transfusion with hae-
moglobin concentration up to 7.0 g/dL, as 
a trigger for RBC transfusion in clinically 
stable children. The well-known treatment 
with exogenous surfactant and corticoster-
oids, and some of the newly proposed pos-
sibilities, such as helium-oxygen mixture, 
inhaled or IV prostaglandins therapy, plas-
minogen activators, fibrinolytics, inhaled 
β-adrenergic receptor agonists or ipratro-
pium, IV N-acetylcysteine, dornase alpha 
outside of the cystic fibrosis population, 
and cough-assist devices - all these have 
not shown clearly their benefits. 
In case of failure of conventional treatment, 
ECMO is currently the last resort, and the 
key to successful survival is the implemen-
tation of ECMO before irreversible organ 
injury develops. ECMO should be consid-
ered to support children with severe ARDS 
where the cause of the respiratory failure 
is believed to be reversible, or the child is 
likely to be suitable for consideration for 
lung transplantation. (4) Extracorporeal 
Life Support Organization (ELSO) annual 
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reports of ECMO use to support paediatric 
patients with respiratory failure is 300-500 
cases/year over last 5 years. (5) 
Recent advances in technology include: 
refinement of double lumen veno-venous 
(VV) cannulas, to support a large range of 
patient size, pumps with lower prime vol-
umes, more efficient oxygenators, changes 
in circuit configuration to decrease tur-
bulent flow and haemolysis. Veno-arterial 
(VA) mode of support remains the pre-
dominant type used; however, VV support 
has lower risk of central nervous injury 
and mortality. (6) Despite that, mortality 
has remained relatively unchanged overall 
(43%) over the past several decades. Risk 
factors associated with death include pro-
longed use of mechanical ventilation (> 2 
wk) prior to ECMO, use of VA ECMO, old-
er patient age, prolonged ECMO support 
and complications during ECMO. (7) Even 
with current state-of-the-art treatment 
regimens and the introduction of PARDS 
recommendation and protocols includ-
ing ECMO, overall mortality rates range 
between 22 and 35% . (2) It is clear that 
PARDS remains a heavy burden on critical 
care providers and hospitals dealing with 
it, due to high morbidity and mortality re-
lated to this syndrome.
CASE REPORT
Eleven months old female infant was ad-
mitted to our hospital because of breathing 
difficulties (tachypnea, dyspnea, and low 
oxygen saturation) due to bronchiolitis. 
Epidemiological history was positive for 
upper respiratory tract infection. Personal 
history revealed that she had been pre-
natally diagnosed with omphalocele. She 
was born in the 37th week of gestation by 
caesarean section and immediately trans-
ferred to our hospital for treatment. The 
infant initially received conservative treat-
ment, which was complicated with difficul-
ties in feeding, stool passage, weight gain 
and prolonged need for oxygenotherapy. 
Gradually normal enteral intake and stool 
passage were established, with normalisa-
tion in respiratory status, and she was dis-
charged with regular follow-ups. 
At the age of 7 months an operation was 
performed (occlusion of omphalocele), 
after which she had been on mechanical 
ventilation for two days, with unevent-
ful postoperative period. In follow-up the 
child was well, without any symptoms, and 
regularly controlled for small ASD and 
mild stenosis of the left branch of the PA 
by paediatric cardiologists. She did not re-
ceive any chronic therapy, her vaccination 
was delayed by primary care paediatrician, 
and she did not meet the criteria for RSV 
immunoprophylaxis.
The girl was admitted to the pulmology 
department for initial symptomatic treat-
ment. Laboratory tests and microbiologi-
cal findings pointed to viral etiology of 
bronchiolitis (Influenza A and RSV +). Af-
ter eight hours she developed acute hyper-
capnic respiratory failure, with impaired 
consciousness, and was transferred to the 
paediatric intensive care unit. Radiogram 
of thoracic organs showed bilateral infil-
trates with substantial elevation of inflam-
matory parameters in blood exams. She 
was intubated, conventionally mechani-
cally ventilated and empirical antibiotic 
therapy with ceftriaxone and azitomycin 
was introduced. PaO2/FiO2 ratio of 205 
and oxygenation index (OI) of 4.8 were 
calculated, which was compatible with a 
mild form of ARDS. After initial stabiliza-
tion, on the second day there was further 
deterioration of respiratory status. There 
was radiologic progression of diffuse in-
filtrates, with PaO2/FiO2 ratio of 73.75 
and OI of 16.27 that were compatible 
with severe ARDS. Further intensive care 
treatment was conducted according to the 
current recommendations– lung protec-
tive ventilation strategy, prone position-
ing with lung recruitment manoeuvres, 
cautious negative fluid balance, endotra-
cheal application of exogenous surfactant 
and finally HFOV. Trophic enteral nutri-
tion and continuous parenteral nutrition 
were delivered. After a few hours, cardiac 
ultrasound revealed signs of pulmonary 
hypertension and right sided heart failure, 
so iNO treatment started, together with 
inotropes and neuromuscular blockade. 
Each of the treatment efforts resulted only 
with transient stabilization and short term 
positive effect on PaO2/FiO2 ratio and OI. 
Respiratory acidosis persisted, with inad-
equate ventilation and oxygenation, so the 
need for ECMO as rescue therapy was in-
dicated.
The child was first placed on veno-venous 
ECMO, which failed to achieve an ad-
equate flow rate. Due to complications, the 
child was reanimated on several occasions. 
Opened chest operation had to be done, 
with placement of the central cannula 
(right atrium and aorta ascendens) and es-
tablishment of veno-arterial ECMO. With 
the adequate volume resuscitation, blood 
derivatives, inotrope and vasopressor sup-
port, circulatory stability and the desired 
flow rates were achieved. Brain ultrasound 
showed normal cerebral blood flow.
Despite that, the child developed signs of 
multiple organ failure; liver failure was 
followed by coagulation disorder that was 
corrected with FFP. Acute renal failure 
with signs of volume overload also devel-
oped, with the need for continuous veno-
venous haemodialysis (CVVHD). With 
V-A ECMO and CVVHD hemodynamic 
and respiratory stability has been finally 
achieved. The anticoagulant prophylaxis 
on ECMO was maintained in accordance 
to the protocol and daily open chest sur-
gical controls were performed. Ventilation 
setting was set in terms of ultra-protective 
ventilation. Bronchoalveolar lavage with 
a diluted surfactant suspension and sur-
factant instillation was applied once more, 
but without any improvement in the sta-
tus of the lung. By close monitoring of the 
neurological status, dilated pupils with no 
reaction to light were noticed, with abnor-
mal EEG recording. Brain CT scan showed 
diffuse intracerebral hematoma with ven-
tricular system compression, small subfal-
cine herniation, and signs of diffuse brain 
oedema, which was treated by conservative 
ICU treatment protocols. After 3 weeks 
of active treatment, the child became ex-
tremely hemodynamically unstable and 
despite the treatment with ECMO, CV-
VHD and maximum dose of vasopressor 
and inotrope support, death occurred.
CONCLUSION
ARDS in children is a condition whose eti-
ology, epidemiology, diagnosis and treat-
ment have been in focus of critical care 
medicine for many years. Every day novel 
and promising therapies are proposed by 
different paediatric clinical studies, includ-
ing ECMO as „rescue“ therapy. ECMO was 
first instituted in neonatal population over 
30 years ago, but even with its development 
and advances in technology, the mortality 
and morbidity remains unacceptably high. 
With our case report we once more em-
phasize the need for further investigation 
and institution of novel effective therapies 
of this syndrome.
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